After breast milk is ingested by the infant, human milk oligosaccharides (HMOs) can tolerate the low pH of the gastrointestinal tract and can resist the degradation of the infant‘s pancreatic enzymes and brush border enzymes. Most of them reach the distal small intestine and colon in intact form and are excreted with the infant's feces, so the absorption rate of HMO is very low. Nevertheless, HMOs play an extremely important role in the growth and development of infants. A large number of studies have reported that HMOs play anti-bacterial, immunomodulatory, and anti-inflammatory effects. These mixed oligosaccharides have multiple functions, such as prebiotics, influence on the microbial composition of the gastrointestinal tract, prevent intestinal pathogen adhesion, and improve host defense capabilities.
Fig.1 Postulated HMO effects. (Bode, 2012)
HMOs are complex glycans formed from glucose (Glc), galactose (Gal), fucose (Fuc), N-acetylglucosamine (GlcNAc) and N-acetylneuraminic acid (Neu5Ac). With a few exceptions, all HMOs are formed by reducing lactose core, which can be enzymatically extended through lacto-N-biose (Galβ1,3-GlcNAc, type 1 LacNAc) or N-acetyllactosamine (Gal-β1,4-GlcNAc, type 2 LacNAc) motifs. Further decoration of these structures can be achieved by adding Fuc residues in α1,2-, α1,3- and α1,4-linkages or adding Neu5Ac residues in α2,3- and α2,6-linkages, thereby providing g an array of Lewis structures and blood group antigens. The structure of HMO is complex, and there are multiple positional isomers and linkage isomers, which makes the separation and analysis of HMOs more complicated and difficult.
Fig.2 Generic building scheme of HMOs (Ayechu-Muruzabal, et al., 2018)
CD BioGlyco provides a variety of production technologies such as chemical methods, whole-cell biotransformation (fermentation), enzyme catalysis (isolated enzyme biotransformation), and chemoenzymatic methods.
CD BioGlyco provides a one-stop solution for HMO research, including HMO separation service, HMO production service, and HMO profiling.
CD BioGlyco provides a variety of advanced technologies including UPLC, HPAEC, PGC, HILIC to help customers isolate low-abundance HMOs, you only need to submit the sample to us.
CD BioGlyco has rich production experience and provides multi-faceted HMO production services including chemical synthesis, whole-cell biotransformation (fermentation), enzyme biotransformation, and chemoenzymatic.
CD BioGlyco is a leading international biotechnology company, focusing on glycobiology research for nearly 20 years. Our years of experience and expertise have won us praise from customers all over the world.
Customers can contact our employees directly and we will respond promptly. If you are interested in our services, please contact us for more detailed information.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.